ANAVEX LIFE SCIENCES CORP (AVXL) Fundamental Analysis & Valuation

NASDAQ:AVXL • US0327973006

5 USD
+0.31 (+6.61%)
At close: Mar 4, 2026
5.01 USD
+0.01 (+0.2%)
After Hours: 3/4/2026, 5:20:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AVXL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

AVXL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVXL as it has an excellent financial health rating, but there are worries on the profitability. AVXL has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. AVXL Profitability Analysis

1.1 Basic Checks

  • In the past year AVXL has reported negative net income.
  • In the past year AVXL has reported a negative cash flow from operations.
  • In the past 5 years AVXL always reported negative net income.
  • AVXL had a negative operating cash flow in each of the past 5 years.
AVXL Yearly Net Income VS EBIT VS OCF VS FCFAVXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • AVXL has a Return On Assets of -30.04%. This is in the better half of the industry: AVXL outperforms 66.35% of its industry peers.
  • AVXL has a better Return On Equity (-31.55%) than 74.04% of its industry peers.
Industry RankSector Rank
ROA -30.04%
ROE -31.55%
ROIC N/A
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
AVXL Yearly ROA, ROE, ROICAVXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AVXL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVXL Yearly Profit, Operating, Gross MarginsAVXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AVXL Health Analysis

2.1 Basic Checks

  • AVXL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AVXL has been increased compared to 5 years ago.
  • There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVXL Yearly Shares OutstandingAVXL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AVXL Yearly Total Debt VS Total AssetsAVXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • AVXL has an Altman-Z score of 35.41. This indicates that AVXL is financially healthy and has little risk of bankruptcy at the moment.
  • AVXL has a Altman-Z score of 35.41. This is amongst the best in the industry. AVXL outperforms 93.65% of its industry peers.
  • There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 35.41
ROIC/WACCN/A
WACCN/A
AVXL Yearly LT Debt VS Equity VS FCFAVXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • AVXL has a Current Ratio of 20.87. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
  • AVXL has a better Current ratio (20.87) than 96.15% of its industry peers.
  • A Quick Ratio of 20.87 indicates that AVXL has no problem at all paying its short term obligations.
  • AVXL's Quick ratio of 20.87 is amongst the best of the industry. AVXL outperforms 96.15% of its industry peers.
Industry RankSector Rank
Current Ratio 20.87
Quick Ratio 20.87
AVXL Yearly Current Assets VS Current LiabilitesAVXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AVXL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.36% over the past year.
EPS 1Y (TTM)16.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • AVXL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.04% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.33%
EPS Next 2Y109.74%
EPS Next 3Y106.31%
EPS Next 5Y64.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVXL Yearly Revenue VS EstimatesAVXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
AVXL Yearly EPS VS EstimatesAVXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

4

4. AVXL Valuation Analysis

4.1 Price/Earnings Ratio

  • AVXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 3.86 indicates a rather cheap valuation of AVXL.
  • AVXL's Price/Forward Earnings ratio is rather cheap when compared to the industry. AVXL is cheaper than 98.65% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AVXL to the average of the S&P500 Index (25.11), we can say AVXL is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.86
AVXL Price Earnings VS Forward Price EarningsAVXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVXL Per share dataAVXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • AVXL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AVXL's earnings are expected to grow with 106.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y109.74%
EPS Next 3Y106.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVXL Dividend Analysis

5.1 Amount

  • AVXL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVXL Fundamentals: All Metrics, Ratios and Statistics

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (3/4/2026, 5:20:01 PM)

After market: 5.01 +0.01 (+0.2%)

5

+0.31 (+6.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09
Earnings (Next)05-11
Inst Owners37.14%
Inst Owner Change15.76%
Ins Owners3.23%
Ins Owner Change1.47%
Market Cap446.75M
Revenue(TTM)N/A
Net Income(TTM)-39.95M
Analysts80
Price Target22.44 (348.8%)
Short Float %23.75%
Short Ratio12.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.31%
Min EPS beat(2)28.1%
Max EPS beat(2)46.52%
EPS beat(4)3
Avg EPS beat(4)20.05%
Min EPS beat(4)-9.44%
Max EPS beat(4)46.52%
EPS beat(8)6
Avg EPS beat(8)14.22%
EPS beat(12)10
Avg EPS beat(12)15.63%
EPS beat(16)12
Avg EPS beat(16)12.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)34.78%
EPS NQ rev (3m)42.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-134.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.86
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 3.53
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)1.3
Fwd EY25.91%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS1.42
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.04%
ROE -31.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.87
Quick Ratio 20.87
Altman-Z 35.41
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y9.33%
EPS Next 2Y109.74%
EPS Next 3Y106.31%
EPS Next 5Y64.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1044.8%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.25%
OCF growth 3YN/A
OCF growth 5YN/A

ANAVEX LIFE SCIENCES CORP / AVXL FAQ

Can you provide the ChartMill fundamental rating for ANAVEX LIFE SCIENCES CORP?

ChartMill assigns a fundamental rating of 3 / 10 to AVXL.


What is the valuation status for AVXL stock?

ChartMill assigns a valuation rating of 4 / 10 to ANAVEX LIFE SCIENCES CORP (AVXL). This can be considered as Fairly Valued.


What is the profitability of AVXL stock?

ANAVEX LIFE SCIENCES CORP (AVXL) has a profitability rating of 1 / 10.


What is the expected EPS growth for ANAVEX LIFE SCIENCES CORP (AVXL) stock?

The Earnings per Share (EPS) of ANAVEX LIFE SCIENCES CORP (AVXL) is expected to grow by 9.33% in the next year.